Document is current
Any future updates will be listed below
-
Authors
Sinisalo, Heikki
Kahilakoski, Olli-Pekka
Souza, Victor H.
Nieminen, Jaakko O.
Rantala, Robin
Tommila, Timo
Usuga, Isabel
Laine, Mikael
Ahola, Oskari
Gallegos, Eva
Kozák, Gábor
Vetter, David Emanuel
Rissanen, Ilkka
Jooß, Andreas
Matsuda, Renan
Soto, Ana M.
Li, Dezhou
Humaidan, Dania
Stenroos, Matti
Roine, Timo
Kičić, Dubravko
Ziemann, Ulf
Ilmoniemi, Risto J.
-
Funding
Funding for this research was provided by:
European Research Council (810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377, 810377)
Research Council of Finland (294625, 349985, 294625)
Business Finland (1752/31/2020, 1752/31/2020, 1752/31/2020, 1752/31/2020, 1752/31/2020, 1752/31/2020, 1752/31/2020, 1752/31/2020)
Novo Nordisk (NNF22OC0080883, NNF22OC0080883, NNF22OC0080883, NNF22OC0080883, NNF22OC0080883, NNF22OC0080883)
- License Information
-
More Information
Article History
Received: 7 February 2025
Accepted: 4 May 2025
First Online: 18 May 2025
Declarations
:
: The preliminary testing in two subjects was not considered a study and no ethics approval was required. The participants gave their written, informed consent, and the testing was carried out in accordance with the declaration of Helsinki. For testing more participants, we have now obtained approval by the ethics committee of the Medical Faculty of Tübingen (project number 724/2024MP1).
: All authors have read and agreed to the published version of the manuscript.
: JON and RJI are inventors of patents for mTMS. HS and VHS are inventors of patent applications for TMS and mTMS.
